A Phase I Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2018
At a glance
- Drugs HQP 1351 (Primary)
- Indications Gastrointestinal stromal tumours; Solid tumours
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 09 Aug 2018 Status changed from not yet recruiting to recruiting.
- 26 Jul 2018 New trial record